B2M and plasma cell myeloma: In 1990, a study of 612 patients enrolled on a Southwest Oncology Group trial confirmed that serum beta-2 ­microglobulin was the most robust prognostic factor for myeloma, and that the prognostic value could be improved further by combining with albumin and age.17